Payment overview · 2025
General Payments
$885.37
46 reported records · 10 companies
Healthcare provider profile · identity verified
Vinutha Raj, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAZLET, NJ · NPI 1437144979
Verified facts
What the public records show
CMS Open Payments records show Vinutha Raj, MD received $885.37 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $353.69 | 40.0% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $188.23 | 21.3% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.05 | 11.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.30 | 9.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.87 | 7.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.37 | 3.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.14 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.24 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.54 | 1.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.94 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $885.37 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $241.13 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $188.23 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $187.40 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $170.88 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $97.05 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.30 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.92 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.92 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.37 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 111 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 91 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 558 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 117 |
| Alprazolam | Alprazolam | 310 | 65 |
| Metformin Hcl | Metformin Hcl | 283 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 264 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 88 |
| Furosemide | Furosemide | 204 | 66 |
| Losartan Potassium | Losartan Potassium | 182 | 50 |
| Lisinopril | Lisinopril | 177 | 46 |
| Gabapentin | Gabapentin | 172 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 50 |
| Azithromycin | Azithromycin | 156 | 117 |
| Tramadol Hcl | Tramadol Hcl | 156 | 31 |
| Simvastatin | Simvastatin | 155 | 46 |
| Omeprazole | Omeprazole | 151 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 44 |
| Valsartan | Valsartan | 121 | 38 |
| Potassium Chloride | Potassium Chloride | 116 | 36 |
| Ezetimibe | Ezetimibe | 114 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 113 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 23 |
| Eliquis | Apixaban | 111 | 27 |
| Ozempic | Semaglutide | 102 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 30 |
| Farxiga | Dapagliflozin Propanediol | 91 | 26 |
| Januvia | Sitagliptin Phosphate | 90 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 23 |
| Trazodone Hcl | Trazodone Hcl | 90 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 55 |
| Montelukast Sodium | Montelukast Sodium | 87 | 21 |
| Alendronate Sodium | Alendronate Sodium | 81 | 27 |
| Fenofibrate | Fenofibrate | 74 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 29 |
| Prednisone | Prednisone | 71 | 40 |
| Meloxicam | Meloxicam | 68 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 16 |
| Xarelto | Rivaroxaban | 67 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 14 |
| Warfarin Sodium | Warfarin Sodium | 60 | 12 |
| Ibuprofen | Ibuprofen | 56 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 19 |
| Glipizide | Glipizide | 53 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 18 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | suppressed |
| Amoxicillin | Amoxicillin | 48 | 29 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | 16 |
| Jardiance | Empagliflozin | 47 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 11 |
| Carvedilol | Carvedilol | 46 | 15 |
| Famotidine | Famotidine | 46 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 13 |
| Diazepam | Diazepam | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 15 |
| Fenofibrate | Fenofibrate,micronized | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 16 |
| Levofloxacin | Levofloxacin | 43 | 35 |
| Cefuroxime | Cefuroxime Axetil | 42 | 38 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 12 |
| Finasteride | Finasteride | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | 11 |
| Promethazine Hcl | Promethazine Hcl | 37 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | 16 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 19 |
| Valacyclovir | Valacyclovir Hcl | 31 | 14 |
| Celecoxib | Celecoxib | 30 | 16 |
| Lactulose | Lactulose | 30 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Nystatin | Nystatin | 24 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Mupirocin | Mupirocin | 21 | 14 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Constulose | Lactulose | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 18 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 14 |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Pimecrolimus | Pimecrolimus | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Tetrabenazine | Tetrabenazine | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $885.37 · 46 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error